Skip to main content

Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans.

Publication ,  Journal Article
Halaweish, AF; Moon, RE; Foster, WM; Soher, BJ; McAdams, HP; MacFall, JR; Ainslie, MD; MacIntyre, NR; Charles, HC
Published in: Chest
October 2013

BACKGROUND: Fluorine-enhanced MRI is a relatively inexpensive and straightforward technique that facilitates regional assessments of pulmonary ventilation. In this report, we assess its suitability through the use of perfluoropropane (PFP) in a cohort of human subjects with normal lungs and subjects with lung disease. METHODS: Twenty-eight subjects between the ages of 18 and 71 years were recruited for imaging and were classified based on spirometry findings and medical history. Imaging was carried out on a Siemens TIM Trio 3T MRI scanner using two-dimensional, gradient echo, fast low-angle shot and three-dimensional gradient echo, volumetric, interpolated, breath-hold examination sequences for proton localizers and PFP functional scans, respectively. Respiratory waveforms and physiologic signals of interest were monitored throughout the imaging sessions. A region-growing algorithm was applied to the proton localizers to define the lung field of view for analysis of the PFP scans. RESULTS: All subjects tolerated the gas mixture well with no adverse side effects. Images of healthy lungs demonstrated a homogeneous distribution of the gas with sufficient signal-to-noise ratios, while lung images from asthmatic and emphysematous lungs demonstrated increased heterogeneity and ventilation defects. CONCLUSIONS: Fluorine-enhanced MRI using a normoxic PFP gas mixture is a well-tolerated, radiation-free technique for regionally assessing pulmonary ventilation. The inherent physical characteristics and applicability of the gaseous agent within a magnetic resonance setting facilitated a clear differentiation between normal and diseased lungs.

Duke Scholars

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

October 2013

Volume

144

Issue

4

Start / End Page

1300 / 1310

Location

United States

Related Subject Headings

  • Young Adult
  • Respiratory System
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Lung Diseases
  • Humans
  • Fluorocarbons
  • Female
  • Contrast Media
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Halaweish, A. F., Moon, R. E., Foster, W. M., Soher, B. J., McAdams, H. P., MacFall, J. R., … Charles, H. C. (2013). Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. Chest, 144(4), 1300–1310. https://doi.org/10.1378/chest.12-2597
Halaweish, Ahmed F., Richard E. Moon, W Michael Foster, Brian J. Soher, H Page McAdams, James R. MacFall, Maureen D. Ainslie, Neil R. MacIntyre, and H Cecil Charles. “Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans.Chest 144, no. 4 (October 2013): 1300–1310. https://doi.org/10.1378/chest.12-2597.
Halaweish AF, Moon RE, Foster WM, Soher BJ, McAdams HP, MacFall JR, et al. Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. Chest. 2013 Oct;144(4):1300–10.
Halaweish, Ahmed F., et al. “Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans.Chest, vol. 144, no. 4, Oct. 2013, pp. 1300–10. Pubmed, doi:10.1378/chest.12-2597.
Halaweish AF, Moon RE, Foster WM, Soher BJ, McAdams HP, MacFall JR, Ainslie MD, MacIntyre NR, Charles HC. Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. Chest. 2013 Oct;144(4):1300–1310.

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

October 2013

Volume

144

Issue

4

Start / End Page

1300 / 1310

Location

United States

Related Subject Headings

  • Young Adult
  • Respiratory System
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Lung Diseases
  • Humans
  • Fluorocarbons
  • Female
  • Contrast Media